Technologies

Organotypic models of ovarian cancer are 3D models containing defined extracellular matrices, such as collagen and fibronectin, ovarian cancer cells with specific genetic/molecular characteristics, and one or more cancer-associated stromal cell types (fibroblasts, mesothelial cells, endothelial cells) to mimic specific metastatic niches of ovarian cancer (omentum, peritoneum, interstitial stroma) and the complex interactions within tumor tissues.

The technology for organic thin film transistors (OTFTs) is suitable for large area electronics, disposable electronics and "Internet of Things" applications. Circuits employing OTFTs can be realized by using very cheap printing technologies. The electrical behavior of these devices is essentially different from the behavior of silicon MOSFETs and, in order to enable circuit design, compact models specific for OTFTs are needed.

The presented technology is an electrical compact model for OTFTs that:

The development of genome editing tools has revolutionized the way we think and deal with genetics. The use of Cas9 or its variants allows modifications of specific sites in the human genome by inducing deletions and insertions in a more or less controlled way. In recent years, a new class of tools for genome editing has emerged: the base editors (BE), which result from the fusion of a modified Cas9, which serves to direct the BE to the target, and an active deaminase acting on the DNA, which mediates the C> T or A> G editing.

Time-correlated single photon counting (TCSPC) is regarded as the “gold-standard” method for fluorescence lifetime measurements. However, TCSPC requires using highly sensitive detectors, not suitable for measurements under bright light conditions, thereby making the use impractical in clinical settings. The invention described here solves this problem by synchronizing the fluorescence detection with an external light source.

The Biocrystal Facility, a large multidisciplinary laboratory established at the Institute of Molecular Biology and Pathology (IBPM) of CNR, in collaboration with the Biochemistry Department of Sapienza University aims at supporting the italian scientists and the pharmaceutical companies in the research to find new drug and vaccine against the endemic and epidemic diseases through structure-based drug design.

The portable device is intended to assess exposure to electromagnetic fields produced by an MRI equipment. The device (dosimeter) allows to improve the analysis and study of the problems related to the exposure of the operators, starting from the technical-scientific aspects related to the exposure, also allowing to create a manual of best practices as well as to improve the professional training of operators.

The virtual dynamic docking, carried out in the MOLBD3 lab of the Institute of Biophysics, allows the identification of new drugs through the structural information deriving from the study of target proteins, responsible for some human pathologies. In particular, we screen drugs or small molecules (commercial/own libraries) against known protein sites, surface cavities, surfaces of protein-protein interactions (fixed/rigid hotspots) or structural transition states (dynamic hotspots).

Plants have a huge potential to contribute to the solution of a large number of issues facing the modern world, ranging from a poor crop yields and problems caused by global climate changing. Our team has been on the forefront of the PCR and NGS applications to plant responses to biotic and abiotic stress. As experts in genomics and plant pathology we are able to accelerate the understanding and use of plant genes and resources.

VisLab laboratory of IMM possesses a latest generation Raman micro-spectroscope equipped for vibrational measurements with high spatial and spectral resolution, at controlled temperature and in fast-imaging. The apparatus can be used to collect information and chemico-physical maps without the need for sample preparation and alteration, therefore for non-destructive studies and in operating conditions.

We developed a procedure aimed at simultaneously treating thousands of C.elegans model organisms, from eggs to old adult, in liquid, in 96- or 384-well plates. This procedure can be used to perform drug and toxicological screening of millions of compounds, in very small volumes and on millions of animals. Thanks to easy handling, semi-automatic analysis can be performed using plate readers or High Content Screening instruments.

The Nikon reference centre at IBPM ( www.imagingplatformibpmcnr.it ) is a microscopy platform for high resolution imaging of fixed samples and live cells (time-lapse video recording, both wide field and confocal spinning disk). Multimodal (fluorescence and transmitted light) and multidimensional (in x,y,z, 4 wavelengths, over time) acquisition modes are in place.

In the last years, genetics played a strategic role in the identification of therapeutic targets for complex diseases. Genetic studies identified thousands of variants contributing to disease onset and/or to the influence of measurable features (phenotypes) impacting health. The mechanism of action by which they modulate diseases and phenotypes is still unknown for the vast majority.

This technology concerns the development of new eco-sustainable UV physical/mineral filters with the aim of offering important innovations per the cosmetic sector. This, encouraged by European initiatives in the Green-Deal context, is constantly looking for new components with improved protection of the human health and the environment.

Lifeshell is an anti-seismic furniture construction concept, which can be used for making wardrobes, tables, desktops, beds. It’s made by timber based panels: highly resistant and flexible, relatively lightweight and inexpensive. Lifeshell benefits from the natural wood elasticity and from smart connections for dissipating the great impact energies occurring during an earthquake. Lifeshell has been designed for resisting partial building collapses, and to provide a safe shell where inhabitants can find refuge.

Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.